• EE77 Bridging the Gap: Why Cost-Effectiveness Analyses of Congenital Heart Interventions Are Critical for Person-Centered Value-Based Care

    Dec 1, 2025, 00:00

  • EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status

    Dec 1, 2025, 00:00

  • EE444 Evaluating the Impact of Different Payment Models on the Cost-Effectiveness and Budget Impact of Cell and Gene Therapies: Eladocagene Exuparvovec As a Case Study

    Dec 1, 2025, 00:00

  • EE167 Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model

    Dec 1, 2025, 00:00

  • EE633 Real-World Cost of Automated Red Blood Cell Exchange for Sickle Cell Disease in Kenya: A Cost-Reimbursement Gap Analysis From a Public Sector Perspective

    Dec 1, 2025, 00:00

  • MSR20 AI Powered SQL for Real-World Data: From Questions to Insights

    Dec 1, 2025, 00:00

  • EE562 Is Less More? Aggregating Health States in State Transition Models

    Dec 1, 2025, 00:00

  • HTA39 Are We SEEing It Yet? The Use of Structured Expert Elicitation Protocols for Decision Making

    Dec 1, 2025, 00:00

  • MSR79 Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Lung Cancer Patients Using Machine Learning

    Dec 1, 2025, 00:00

  • PT16 Patients’ Advocacy Groups in Italy: An Updated Perspective on Activities and Future Directions

    Dec 1, 2025, 00:00

  • EE534 Impact of Inclusion of Drug Adherence on Cost-Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Disease (ASCVD) Patients

    Dec 1, 2025, 00:00

  • EPH32 Budget Impact of an Organized Screening Program for Chronic Kidney Disease in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • EE22 A Model-Based Analysis of the Impact on Labor Market Supply From Enhanced Tobacco Control Strategies in Denmark

    Dec 1, 2025, 00:00

  • PCR135 Improving Patient Involvement in Cancer Clinical Trials: Development of Plain Language Checklists Within the SISAQOL-IMI Initiative

    Dec 1, 2025, 00:00

  • HPR219 Timing Matters: Missed Opportunity to Prevent RSV Cases in Older Adults in Germany: A Markov Model Analysis

    Dec 1, 2025, 00:00

  • EPH62 Diabetes Trends in France (2021-2023): A Descriptive Study Based on the THIN Database

    Dec 1, 2025, 00:00

  • CO6 Addressing Clinical Uncertainties in ATMP Reimbursement: A Review of European Methodological Guidelines and Practices

    Dec 1, 2025, 00:00

  • HTA240 National Implementation of the EU HTA Regulation: Progress and Strategic Developments Across Member States

    Dec 1, 2025, 00:00

  • HTA25 Advancing a Greener Ecosystem in Health Technology Assessment: A Review of Environmental Integration as an Additional Value Driver

    Dec 1, 2025, 00:00

  • HTA280 Reassessment of Orphan Drugs in Germany After Exceeding the Annual Sales Limit of €30 Million: Impact on the Reimbursement Price and Key Influencing Factors

    Dec 1, 2025, 00:00

  • EE345 Early Adoption of New Combination Biologic Therapy Enabled by Enhanced Diagnostic Accuracy in Inflammatory Bowel Disease (IBD) Can Be a Budget-Neutral Approach: A Budget Impact Analysis in Italy

    Dec 1, 2025, 00:00

  • EPH185 Predictors of Effectiveness of Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis

    Dec 1, 2025, 00:00

  • HSD50 Examination of Muscle Activity Among Aesthetic Sports Athletes

    Dec 1, 2025, 00:00

  • EE310 Cost-Utility Analysis of the BCIS Conveyance Algorithm for Out-of-Hospital Cardiac Arrest Patients

    Dec 1, 2025, 00:00

  • EE429 Estimation of Utility Weights for Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Covalent Bruton Kinase Inhibitor (cBTKi)

    Dec 1, 2025, 00:00

  • CO108 Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

    Dec 1, 2025, 00:00

  • EPH125 High All-Cause Hospitalization Among Those With Recurrent ASCVD Event: Evidence From a Large-Scale Real-World Database

    Dec 1, 2025, 00:00

  • HTA321 The Interim Acceptance and Ultraorphan Pathways in Scotland: An Update

    Dec 1, 2025, 00:00

  • EE194 Cost-Effectiveness Analysis of Cariprazine vs. Risperidone for the Treatment of Schizophrenia With Predominantly Negative Symptoms (PNS) in United Arab Emirates

    Dec 1, 2025, 00:00

  • EPH53 Cost-Effectiveness Analysis of the 13-Valent Pneumococcal Conjugate Vaccine Compared With Higher-Valent Alternatives in the Pediatric Population of Paraguay

    Dec 1, 2025, 00:00

  • Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Dec 1, 2025, 00:00

  • MSR37 Artificial Intelligence-Powered Literature Reviews (AILRs): Streamlining Joint Clinical Assessment (JCA) Dossier Preparation for the Next Generation of Pharmaceutical Submissions

    Dec 1, 2025, 00:00

  • RWD14 AI-Assisted Expert Computable Operation Definition (CODef) Development for Real-World Research

    Dec 1, 2025, 00:00

  • SA53 Impact of the Severity of Disease-Related Malnutrition on Healthcare Resource Utilization in Pediatric Patients 1 Year and Older

    Dec 1, 2025, 00:00

  • EE641 Reducing External Plasma Dependency: Impact for the Portuguese National Health Service

    Dec 1, 2025, 00:00

  • EE431 Evaluating Cost-Consequences and Digital Transformation Through Concentric Consent: An Impact Assessment at Oxford University Hospitals NHS Foundation Trust

    Dec 1, 2025, 00:00

  • HTA58 Bridging the Uncertainty: Cancer Drugs Fund Entry and Exit Outcomes Over Three Years

    Dec 1, 2025, 00:00

  • SA32 Developing Best Practice for Using Automation Tools in Literature Reviews

    Dec 1, 2025, 00:00

  • CO179 Pharmacist-Led Education Improves Inhaler Satisfaction Adherence and Asthma Control in Asthma Patients

    Dec 1, 2025, 00:00

  • EE637 Real-World Healthcare Resource Utilization and Costs by Glycemic Control in People With Type 2 Diabetes: An Observational Population-based Register Study in Sweden

    Dec 1, 2025, 00:00

  • EPH248 The Incidence, Mortality, and Survival of Metastatic Colorectal Cancer (CRC) per TNM Stages in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • EE360 Economic Burden of Gaucher Disease: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • OP8 Frameworks for the Use of AI Within HEOR: A Targeted Literature Review and Thematic Analysis

    Dec 1, 2025, 00:00

  • RWD69 Economic and Clinical Insights Into Oral Nutritional Supplementation in Oncology: A Brazilian Real-World Study

    Dec 1, 2025, 00:00

  • HTA40 Are We There Yet? Mapping Member State Readiness for Local Implementation of the EU Health Technology Assessment (HTA) Regulation

    Dec 1, 2025, 00:00

  • RWD129 Occupational Disease Claims and Payments in Indonesia: Insights From Administrative Data 2018-2022

    Dec 1, 2025, 00:00

  • MT11 Cost Analysis of the Extravascular Implantable Cardioverter-Defibrillator Compared to the Subcutaneous System in Patients at Risk of Sudden Cardiac Death in Italy

    Dec 1, 2025, 00:00

  • HTA74 Clinical and Economic Factors Underlying QALY Weights and Severity Modifiers in NICE Health Technology Evaluations: An Analysis of Recent Appraisals

    Dec 1, 2025, 00:00

  • PCR155 Measuring Quality of Life in Huntington’s Disease Using a Proxy Approach: Validation of the HD-mQoL-prx Measure

    Dec 1, 2025, 00:00

  • EE475 Five-Year Clinical and Economic Impact of 20 Weight Loss in Adults With Obesity in Saudi Arabia: A Public Healthcare Perspective

    Dec 1, 2025, 00:00

  • EE88 Budget Impact Analysis of Inclisiran for the Management of Patients With Atherosclerotic Cardiovascular Disease in India: A Multipayer Analysis

    Dec 1, 2025, 00:00

  • EPH9 A Systematic Literature Review to Identify Potential Risk Factors and Causative Organisms for Neonatal Sepsis in Indian Neonates

    Dec 1, 2025, 00:00

  • HPR28 Are We Getting Good Value for Innovative Therapies in the US? Findings From Generalized Cost-Effectiveness Analyses (GCEAs)

    Dec 1, 2025, 00:00

  • HPR185 Small Molecules vs. Biologics Patterns of Indication Expansion and the Potential Impact of Medicare Price Negotiation

    Dec 1, 2025, 00:00

  • PCR146 Involving Women With Lived Experience of Pelvic Organ Prolapse in Designing and Refining the Economic Components of a Health Technology Assessment

    Dec 1, 2025, 00:00

  • HTA12 A Retrospective Assessment of Drug Eligibility for NICE’s Highly Specialized Technologies Program Using the 2025 Criteria

    Dec 1, 2025, 00:00

  • PCR202 Quality of Life in Patients With Severe Hemophilia A With Inhibitors Treated With Emicizumab in Mexico

    Dec 1, 2025, 00:00

  • PT18 Evaluating AI Chatbot Empathy and Probing Skills in Automated Patient In-Trial Interviews: A Proof of Principle Experiment

    Dec 1, 2025, 00:00

  • RWD158 Real-World Healthcare Resource Utilization and Related Costs Associated With Bladder Cancer in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • HTA295 Routing Decisions and Outcomes of NICE Technology Appraisals Underproportionate Approach to Technology Appraisals

    Dec 1, 2025, 00:00

  • HTA364 What Has Worked Well in Fabry Disease? An HTA Landscape Assessment Study

    Dec 1, 2025, 00:00

  • MSR64 Country-Related Differential Item Functioning in the EQ-5D-5L: Insights From the EuroQol Data Assessment of Population Health Needs and Instrument Evaluation (EQ-DAPHNIE)

    Dec 1, 2025, 00:00

  • RWD21 Assessing the Feasibility of the Implementation of a Subscription Model Pricing Solution Aimed at Broadening Access to All Eligible Patients Within the HER2 Indication

    Dec 1, 2025, 00:00

  • RWD155 Real-World Evidence of Atezolizumab in Unresectable Recurrent NSCLC: Insights From Japan's Next-Generation Medical Infrastructure Act

    Dec 1, 2025, 00:00

  • EE319 Decluttering Complexity: A Pragmatic Framework for Simplifying Global Health Economic Models for HTA

    Dec 1, 2025, 00:00

  • HTA306 Surrogate Endpoints in German Health Technology Assessment: Post Hoc Analyses of the Phase III PROTECT Study Highlight the Efficacy of Sparsentan in Slowing Down the Loss of Kidney Function in IgAN Patients

    Dec 1, 2025, 00:00

  • MSR55 Clinically Informed, Cost-Sensitive Machine Learning for Predicting Hospital-Acquired Pressure Injuries: A Practical Approach Using Routinely Collected Data

    Dec 1, 2025, 00:00

  • CO9 An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal-Bolus Insulin

    Dec 1, 2025, 00:00

  • SA104 When Trials Don’t Meet: A Retrospective Statistical Analysis Using Matching-Adjusted Indirect Comparison (MAIC) and Individual Patient Data (IPD) to Compare Catiolanze® With Other Preservative-Free (PF) Latanoprost in Open-Angle Glauc ...

    Dec 1, 2025, 00:00

  • EE688 The Clinical Humanistic and Economic Burden of the Current Management of Patients With Recurrent Malignant Ascites in the UK and Europe

    Dec 1, 2025, 00:00

  • HTA220 Life Years Generated for Relapsed/Refractory Mantle Cell Lymphoma Patients Managed on CAR-T in an England NHS Setting

    Dec 1, 2025, 00:00

  • EE112 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in France

    Dec 1, 2025, 00:00

  • SA54 Indirect Comparison of Tarlatamab vs. Chemotherapy (CTx) in Patients With Previously Treated, Platinum-Refractory, or Resistant Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Dec 1, 2025, 00:00

  • EPH154 Knowledge and Awareness of Primary Care Physicians (PCPs) Towards Respiratory Syncytial Virus (RSV) in Australia, Hong Kong, Japan, New Zealand, South Korea, Singapore, and Taiwan

    Dec 1, 2025, 00:00

  • HTA111 Differential HTA Recommendations for Continuous Glucose Monitors (CGMs): A Global Comparative Review of HTA Focus, Challenges, and Solutions

    Dec 1, 2025, 00:00

  • EE690 The Cost of Pressure: Quantifying the Consequences of Clinical Strain in Ophthalmology

    Dec 1, 2025, 00:00

  • CO131 Health-Related Quality of Life (HRQoL) in Duchenne Muscular Dystrophy (DMD): Insights From the DMD-QoL Instrument in the United States (US)

    Dec 1, 2025, 00:00

  • HTA23 Addressing Payer Concerns: Opportunities for HEOR in Orphan Drug Development

    Dec 1, 2025, 00:00

  • HTA120 Economic Assessments of Rare Disease Drugs in Fran Insights From CEESP Opinions Reviews

    Dec 1, 2025, 00:00

  • EPH116 Grounded Theory Study to Assess Barriers and Reasons for Insufficient Compliance With Valproate Risk Minimization Measures: Example of a Qualitative Method Aligned With the Recommendations of the GVP Module XVI, Addendum II

    Dec 1, 2025, 00:00

  • EPH37 Cardiovascular Implications of Loneliness and Social Isolation: Evidence From a Systematic Review

    Dec 1, 2025, 00:00

  • MSR33 Are Economic Models in R That Shiny? Making Cost-Effectiveness Models Shinier by Integrating Artificial Intelligence Applications

    Dec 1, 2025, 00:00

  • EE294 Cost-Substitution and Hospital Diagnosis-Related Group (DRG) Performance Impact Analysis of Infliximab Biosimilar Adoption in Moderate-to-Severe Crohn's Disease Patients in China

    Dec 1, 2025, 00:00

  • P22 Validation of Primary Care Resource Use and Costs in OMOP-Mapped vs. Source CPRD Aurum Data

    Dec 1, 2025, 00:00

  • HTA206 Integrating Patient Perspectives in HTA: What Can We Learn to Inform HTA-Focused Value Communications?

    Dec 1, 2025, 00:00

  • SA78 Quality of Systematic Reviews With Network Meta-Analyses on JAK Inhibitors in the Treatment of Rheumatoid Arthritis: Application of the AMSTAR 2 Scale

    Dec 1, 2025, 00:00

  • MSR114 Generalizability of a Randomized Clinical Trial-Based Prediction Model in a Real-World Population

    Dec 1, 2025, 00:00

  • MSR87 Estimand Framework in the Setting of Observational Studies: Current Landscape and Future Directions

    Dec 1, 2025, 00:00

  • EE505 Healthcare Resource Use and Direct Healthcare Costs Associated With Respiratory Syncytial Virus Infections in Individuals Aged 18 Years or Older in Italy: A Retrospective Observational Study

    Dec 1, 2025, 00:00

  • HTA365 What Is Driving the Increase in Terminated NICE Appraisals?

    Dec 1, 2025, 00:00

  • CO146 Improving Colorectal Cancer Surgical Outcomes Through Audit and Feedback: Results From the Emilia Romagna ESCA Program

    Dec 1, 2025, 00:00

  • EE459 Exploring the Healthcare Resource Utilization (HCRU) Associated With Chorea in Patients With Huntington's Disease (HD): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HTA37 Applying the Evidence-Generation Continuum Concept to Support Patient Access to Innovative Therapies in Fran A Use Case in Rare Diseases

    Dec 1, 2025, 00:00

  • PCR10 A Review of Information Uncertainty in Oncology Treatment Preferences

    Dec 1, 2025, 00:00

  • EE320 Deep Brain Stimulation: A Cost-Saving Treatment Option for Extreme Treatment-Refractory Obsessive-Compulsive Disorder in the UK?

    Dec 1, 2025, 00:00

  • EE283 Cost-Minimization Analysis of Aripiprazole 2-Month Ready-to-Use vs. Other Long-Acting Injectable Antipsychotics: Evidence From Ontario

    Dec 1, 2025, 00:00

  • EE593 Multistakeholder Survey on Communication of Uncertainties in Cost-Effectiveness Analysis by the Institute of Clinical and Economic Review

    Dec 1, 2025, 00:00

  • PCR86 Evaluation of the Effectiveness of a Naturalness Probe for Assessing Human- and Nonhuman-Generated COA Translations in Linguistic Validation Cognitive Debriefing Interviews

    Dec 1, 2025, 00:00

  • EE110 Budget Impact of Metyrapone for the Treatment of Cushing’s Syndrome in France

    Dec 1, 2025, 00:00

  • HSD67 Knowledge and Practices Regarding Expired Medications Among Saudi Citizens

    Dec 1, 2025, 00:00

  • RWD9 Advanced Therapies and the Unmet Need in Systemic Lupus Erythematosus Patients: Results From a Real-World Study in the United States and Germany

    Dec 1, 2025, 00:00

  • HPR81 Evolution of National Price Negotiations for Pharmacy/Retail Medicines (Triparty Negotiations) in Sweden and Implications for Access

    Dec 1, 2025, 00:00

  • EE508 Healthcare Resource Utilization (HCRU) Analysis in Newly Diagnosed Mantle Cell Lymphoma: Autologous Stem Cell Transplantation (ASCT) and (HCRU) Alleviation With Adoption of the TRIANGLE Ibrutinib Regimen Without (ASCT)

    Dec 1, 2025, 00:00

  • MSR180 Reevaluating Cost-Effectiveness: A Holistic Framework for Assessing Disease-Modifying Treatments in Type 1 Diabetes

    Dec 1, 2025, 00:00

  • MSR150 Modeling Physician Prescribing Decisions Based on Patient Characteristics for Positioning of a Novel Treatment Entering a Well-Established Category

    Dec 1, 2025, 00:00

  • RWD64 Director Primary Data Collection

    Dec 1, 2025, 00:00

  • PCR62 Development of the Adelphi Caregiver Experience Questionnaire© (ACARE): A Novel Tool Designed to Measure and Understand the Burden and Quality of Life Impacts of the Caregiver Role

    Dec 1, 2025, 00:00

  • HPR187 Socioeconomic Disparities in Postpartum Depression Following Abortion Restrictions: A Difference-in-Differences Analysis of Medicaid Data Post-Dobbs

    Dec 1, 2025, 00:00

  • RWD135 Persistence With Osteoporosis Medication Treatments Among Chinese Patients With Osteoporosis: A Retrospective Cohort Study

    Dec 1, 2025, 00:00

  • HTA113 Disparities in Market Access of ATMPs: A Comparative Analysis of HTA Outcomes Across Europe

    Dec 1, 2025, 00:00

  • HTA17 Acceptability of Early Endpoints in NICE Appraisals for Adjuvant and Neoadjuvant Oncology Therapies

    Dec 1, 2025, 00:00

  • EE153 Constructing a Dynamic Budget Impact Model: An AI Pretraining Approach for a New Parkinson's Disease Drug

    Dec 1, 2025, 00:00

  • PCR256 Unseen Burdens of Glycogen Storage Disease Type Ia (GSDIa) Experienced by Patients, Caregivers, and their Healthcare Team

    Dec 1, 2025, 00:00

  • HTA84 Comparing ROBINS-I V2 and Downs Black for nRCTs in the Context of HTA

    Dec 1, 2025, 00:00

  • EE385 Economic Evaluation of Surfactant Therapy for Neonatal Respiratory Distress Syndrome: 5-Year Real-World Evidence on Poractant Alfa vs. Beractant From the IMSS Perspective in Mexico

    Dec 1, 2025, 00:00

  • HSD26 Comparing Countries’ Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States

    Dec 1, 2025, 00:00

  • CO67 Current Methodological Practices to Define Within-Patient Meaningful Change in Rare Diseases: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • RWD90 Granulocyte-Colony Stimulating Factor (G-CSF) Reference and Biosimilar Products Using Real-World Data to Assess Data Variability Across Different Sources to Evaluate its Potential Utility in Regulatory Assessment: A Study by the Biolo ...

    Dec 1, 2025, 00:00

  • HPR46 Comparative Analysis of Access and Pricing Timelines for Innovative Medicines in the US, Europe, and Japan Pre- and Post-Pricing Reform 2021-2025

    Dec 1, 2025, 00:00

  • HPR231 Unmet Need in IgA Nephropathy (IgAN): Disparity Between Clinical Guidelines and Real-World Practice in Ireland

    Dec 1, 2025, 00:00

  • MSR26 An Update on the Evolving Use of Artificial intelligence and Machine Learning (AI/ML) in Systematic Literature Reviews (SLRs)

    Dec 1, 2025, 00:00

  • SA92 Testing Automated-Prompt Engineering Strategies for Systematic Literature Review Screening

    Dec 1, 2025, 00:00

  • PCR238 The PAVING II Interview Study: Assessing Evolving Patient Preferences Regarding Gene Therapy for Hemophilia Patients

    Dec 1, 2025, 00:00

  • PCR245 To What Endpoint? Exploring Clinical Outcome Assessments of Pain in Phase 2 and 3 Trials and Drug Labels in Women’s Health Conditions

    Dec 1, 2025, 00:00

  • EE708 The Five-Year Budget Impact of Introducing Semaglutide 2.4 mg for Obesity Management in Saudi Arabia: A Real-World Patient Flow and Complication-Driven Model

    Dec 1, 2025, 00:00

  • SA6 Addressing Bias in Indirect Treatment Comparisons: A Framework for Identifying TEMs and PVs

    Dec 1, 2025, 00:00

  • SA89 Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in the UK

    Dec 1, 2025, 00:00

  • HSD109 The Real-World Impact of Step Therapy and Prior Authorization on Patients, Clinicians, and US Health Plans: Lessons to Be Learned in Europe

    Dec 1, 2025, 00:00

  • PT22 Advanced Therapy Medicinal Products From Promise to Practi Understanding Reimbursement and Access Disparities in Western Europe

    Dec 1, 2025, 00:00

  • SA79 Real-World Treatment Patterns Among Patients Newly Diagnosed With Chronic Inflammatory Demyelinating Polyneuropathy in the United States

    Dec 1, 2025, 00:00

  • HTA69 Challenges at the Interface Between EUHTA (JCA) and National HTA in Germany (AMNOG): Expected Limitations to Synergy Effects and Implications for AMNOG Dossier Preparation

    Dec 1, 2025, 00:00

  • HPR89 Facilitating Investment in Obesity Care and Prevention: A Societal Cost Benefit Analysis for the Netherlands

    Dec 1, 2025, 00:00

  • HTA79 Comparative Clinical Effectiveness in Skin Cancer: Lessons From HTA Decision Making in EU4, UK, and Australia

    Dec 1, 2025, 00:00

  • HTA179 How Impactful Is Time to Next Treatment on Health Technology Assessment Outcomes in Indolent Cancers?

    Dec 1, 2025, 00:00

  • HTA177 Healthstate Utilities for Hormone Receptor-Positive (HR+) Human Epidermal Growth Factor-Receptor 2 Negative (HER2-) Breast Cancer

    Dec 1, 2025, 00:00

  • MSR71 Development of an A-Powered Command-Line Agent to Support Methodological Guidance Selection in Health Economics Analysis

    Dec 1, 2025, 00:00

  • HTA126 Environmental Sustainability in HTA: To What Extent Are HTA Bodies Considering Environmental Considerations in Their Decision Making?

    Dec 1, 2025, 00:00

  • HSD85 Persistence of Anticholinergic Agents in Patients With Overactive Bladder: A Cohort Study From the French National Health Insurance Claim Database (SNDS)

    Dec 1, 2025, 00:00

  • EE554 Informing Value-Based Pricing: Cost-Effectiveness Analysis of a Hypothetical First-Line Therapy for Metastatic Pancreatic Cancer

    Dec 1, 2025, 00:00

  • EE451 Examining the Opportunity Costs Due to Diabetic Macular Edema Taking Into Account Access Barriers Evaluated in the Barometer Program Survey in Colombia

    Dec 1, 2025, 00:00

  • RWD148 Real-World Associations Between Smoking Status and Genetic Driver Mutations in Metastatic Lung Cancer in US Community Oncology

    Dec 1, 2025, 00:00

  • RWD187 Understanding Treatment Preferences in Highly Sensitized ESKD Patients: A Latent Profile Analysis of Discrete Choice Data

    Dec 1, 2025, 00:00

  • CO171 NMAs of Systemic Therapies for Advanced Biliary Tract Cancer: A Systematic Review and Critical Appraisal Using RoB NMA

    Dec 1, 2025, 00:00

  • EE630 Quantifying the Opportunity Costs of Intra-Direct Oral Anticoagulants (DOAC) Switching Pathways Across the National Health Service (NHS) in England: A Structured Framework

    Dec 1, 2025, 00:00

  • CO57 Comparative Efficacy of First-Line (1L) Therapies for Patients With Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Updated Systematic Literature Review (SLR) and Bayesian Network Meta-Analys ...

    Dec 1, 2025, 00:00

  • MSR138 Linking Specialty Pharmacy Data With Healthcare Claims Data in a Rare Disease: Comprehensively Characterizing Patients With Hereditary Angioedema Treated With Berotralstat

    Dec 1, 2025, 00:00

  • CO49 Clinical Outcomes In HTA Appraisal Reports Of Oncology Medicines In Portugal: A Cross-Sectional Analysis

    Dec 1, 2025, 00:00

  • PCR220 Spillover Effects on Informal and Family Caregivers' Utility: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HSD107 The Evolving Role of Pharmacists as Vaccinators in New Zealand and Denmark

    Dec 1, 2025, 00:00

  • OP14 Linking Data to Care: Mining the Pathways of Oncology

    Dec 1, 2025, 00:00

  • HTA352 Using External Clinical Evidence to Inform Local Health Policy: The Tradeoff Between Early Access and Uncertainty

    Dec 1, 2025, 00:00

  • HPR237 Value of the France Early Access Pathways: Highlighting Benefits for Patients and Industry Sponsors of the Novel Therapeutic Fosmanogepix Addressing High Unmet Clinical Needs in Invasive Fungal Infections

    Dec 1, 2025, 00:00

  • MT43 Unlocking Value Early: Insights Into NICE’s Early Value Assessments and Evidence-Generation Plans for Medical Technologies

    Dec 1, 2025, 00:00

  • HPR108 Global Payer Policies Potentially Impacting Pharma Pricing and Market Access Strategies: A Review of Five Key Trends Shaping Pharma Future

    Dec 1, 2025, 00:00

  • RWD139 Quality and Impact of Real-World Data in Chronic Disease Research: Insights From Retrospective Studies Using the Hospital Episode Statistics (HES) Database

    Dec 1, 2025, 00:00

  • HPR147 Navigating the MFN Pricing Era: Strategic Imperatives for Biopharma

    Dec 1, 2025, 00:00

  • EPH50 Comparative Epidemiological Burden of Osteoarthritis in Eastern Central and Western Europe Based on the Global Burden of Disease Study 2021

    Dec 1, 2025, 00:00

  • SA1 A Comprehensive Assessment of Clinical Studies on Artificial Intelligence-Enabled Interventions: Uncovering Trends and Potential Implications

    Dec 1, 2025, 00:00

  • HPR197 The Disease Burden of Respiratory Syncytial Virus Among the Adult Population in Greece

    Dec 1, 2025, 00:00

  • MSR142 Machine Learning to Predict Noncompliance and Program Dropout in Patients Treated for Chronic Diseases: Unsupervised and Supervised Analyses From a Large Multinational Drug Access Program Database

    Dec 1, 2025, 00:00

  • PCR51 Concordance Between Patient and Physician Reporting of Symptoms for Metastatic Urothelial Cancer in Europe: A Real-World Survey

    Dec 1, 2025, 00:00

  • EE645 Reforming the Delivery of Smoking Cessation: A Distributional Cost-Effectiveness Analysis of Providing Smoking Cessation as Part of Targeted Lung Cancer Screening in England

    Dec 1, 2025, 00:00

  • MT21 Generative A-Powered Extraction of Immune-Related Adverse Events From Oncology Case Reports

    Dec 1, 2025, 00:00

  • CO120 Extending Survival in Glioblastoma: Real-World Evidence of Post-Progression Benefit From Tumor-Treating Fields Therapy

    Dec 1, 2025, 00:00

  • EE436 Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands

    Dec 1, 2025, 00:00

  • EE61 Assessing the Economic Impact of Biosimilars in Europe: A Cost Analysis of Infliximab, Trastuzumab, and Rituximab

    Dec 1, 2025, 00:00

  • HTA110 Differences in the Reimbursement Pathway for Ultraorphan Therapies in England and Ireland

    Dec 1, 2025, 00:00

  • EPH2 A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population

    Dec 1, 2025, 00:00

  • EE236 Cost-Effectiveness of Artificial Intelligence Interventions for Musculoskeletal Disorders: Systematic Review

    Dec 1, 2025, 00:00

  • EE364 Economic Burden of Progressive Pulmonary Fibrosis (PPF) in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • SA88 Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in France, Italy, Spain, and Germany

    Dec 1, 2025, 00:00

  • EE304 Cost-Utility Analysis of Linzagolix 200 mg Plus Add-back Therapy (Linzagolix+ABT) for Symptomatic Treatment of Endometriosis

    Dec 1, 2025, 00:00

  • CO47 Clinical Expert Opinion on the Impact of Vosoritide on Health and Function in Children With Achondroplasia

    Dec 1, 2025, 00:00

  • RWD184 Treatment Patterns and Healthcare Costs of Newly Diagnosed Type 1 Diabetes Patients: A Retrospective Real-World Study of Hospital Care in Tianjin, China

    Dec 1, 2025, 00:00

  • CO238 The Clinical Impact of Screening Blood Donations for Hepatitis E Virus in Catalonia

    Dec 1, 2025, 00:00

  • EE513 Healthcare Resource Utilization and Economic Burden Among Adults With Alopecia Areata in the Kingdom of Saudi Arabia

    Dec 1, 2025, 00:00

  • EE32 A Systematic Literature Review of Cost of Illness Studies on Atrial Fibrillation With Focus on the Methodologies Economic Burden and Factors Influencing the Cost of Atrial Fibrillation Among European and North American Countries

    Dec 1, 2025, 00:00

  • EE210 Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole for the Treatment of Invasive Aspergillosis in Morocco

    Dec 1, 2025, 00:00

  • RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care

    Dec 1, 2025, 00:00

  • EE251 Cost-Effectiveness of First-Line Lorlatinib for ALK-Positive Advanced NSCLC in the UK

    Dec 1, 2025, 00:00

  • MSR197 The Effects of Pooling Treatment Effects Targeting Treatment Policy and Hypothetical Estimands With Rank-Preserving Structural Failure Time Model in Oncology Aggregate-Level Meta-Analyses

    Dec 1, 2025, 00:00

  • PCR5 A Data-Driven Framework for Rare Disease Protocol Design: Integrating Real-World Evidence, Patient Perspectives, and Regulatory Guidance

    Dec 1, 2025, 00:00

  • EE676 Surviving but Not Earning? Long-term Income Trajectories in Working-Age mIDH Glioma Patients: Stratification by Radiotherapy/Chemotherapy Exposure

    Dec 1, 2025, 00:00

  • EPH257 Transition Across Cognitive States and Death Among Older Adults With Type 2 Diabetes: Determining the Predictors of Cognitive Decline With a Multistate Markov Model

    Dec 1, 2025, 00:00

  • HPR38 Bridging the Gap: What Spain Can Learn From European Leaders in Digital Therapy Reimbursement

    Dec 1, 2025, 00:00

  • RWD50 Data Linkage to Support Real-World Evdence in Rare Disease

    Dec 1, 2025, 00:00

  • EPH122 Healthcare Resource Use in Uncontrolled Hypertension: An Observational Study in England Using Electronic Health Records

    Dec 1, 2025, 00:00

  • HPR121 Incentivizing Access to New Drugs in Psychiatry: Exploration of a Subscription Payment Approach to Overcome Barriers to European Launch

    Dec 1, 2025, 00:00

  • HSD42 Effectiveness of Community Health Worker vs. Professional Care in Obesity Management: Preliminary Findings From a SMART Trial

    Dec 1, 2025, 00:00

  • CO88 Effectiveness of Subcutaneous Natalizumab in Multiple Sclerosis: Real-World Evidence From a Finnish Registry Study

    Dec 1, 2025, 00:00

  • RWD147 Real-World Assessment Process to Identify Fit-for-Purpose Data Sources to Meet Milestones for Post-Marketing Requirements (PMR), Post Authorization Safety Studies (PASS), and Health Technology Assessment (HTA) Submissions Utilizing S ...

    Dec 1, 2025, 00:00

  • EE399 Economic Impact of Incorporating a Fecal Bacterial Signature to Optimize FIT-Based Colorectal Cancer Screening in Spain

    Dec 1, 2025, 00:00

  • HSD77 Number of Inquiries for a Second Course of Teprotumumab in the US Over Four Years

    Dec 1, 2025, 00:00

  • SA66 Measurement Properties of the EQ-5D in Hematological Cancers: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR2 A Collection Of Essays on Patient Centricity in Intervention Development

    Dec 1, 2025, 00:00

  • EE373 Economic Evaluation of a Standardized Care Pathway for Nontraumatic Acute Abdominal Pain in the Emergency Department

    Dec 1, 2025, 00:00

  • HTA122 Effectiveness and Safety of Radiofrequency Nucleolysis for Chronic or Acute Low Back Pain

    Dec 1, 2025, 00:00

  • PCR123 Hybrid Digital Support for Patients Receiving Adalimumab Therapy for Immune-Mediated Inflammatory Disorders: 12-Month Persistence and Impact on Adherence

    Dec 1, 2025, 00:00

  • CO119 Exploring the Association Between Treatment Effects on Cure Rates and Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis (CMA) of Randomized Controlled Trials (RCTs)

    Dec 1, 2025, 00:00

  • EE742 Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Germany: A Return on Investment Analysis Using an Integrated Actuarial-Macroeconomic Model

    Dec 1, 2025, 00:00

  • EE193 Cost-Consequence of Incorporating Single-Operator Direct Visualization Cholangioscopy in the Diagnosis of Indeterminate Biliary Strictures in Saudi Arabia

    Dec 1, 2025, 00:00

  • CO261 Using Structured Expert Elicitation to Estimate Long-Term Organ Damage Risk in an Ultrarare Condition: A STEER Case Study

    Dec 1, 2025, 00:00

  • CO202 Real-World Effectiveness of Oral Semaglutide in Thai Patients With Type 2 Diabetes: An Observational Single-Arm Multicenter Retrospective Cohort Study (REALISED)

    Dec 1, 2025, 00:00

  • PCR269 Why Are Patient-Reported Outcome Measure (PROM) Results Missing From Labels of Obesity Management Medications?

    Dec 1, 2025, 00:00

  • EPH15 Analysis of Factors Behind Differences Between Official Drug Pricing and Cost-Effectiveness Evaluation in Japan and Policy Implications

    Dec 1, 2025, 00:00

  • EE479 Gender Differences in the Economic Burden of Alcohol Use in Belgium

    Dec 1, 2025, 00:00

  • CO34 Budget Impact of a PreTRM-Guided Preventive Bundle for Preterm Birth in Low-Risk Pregnancies: A Microsimulation Study Using PRIME Trial Data

    Dec 1, 2025, 00:00

  • EE741 Understanding the Impact of the NICE Severity Modifier: A Targeted Review of Oncology Submissions

    Dec 1, 2025, 00:00

  • CO251 Time to and Time in Better Health States With Sotatercept for Pulmonary Arterial Hypertension: A Modeling Study

    Dec 1, 2025, 00:00

  • HSD94 Real-World Evidence on Treatment Patterns and Guidelines in Patients With Advanced Merkel Cell Carcinoma Across the US and Europe

    Dec 1, 2025, 00:00

  • MSR227 Zoom Out: Simplifying Complex Health Economic Model Structure Through Artificial Intelligence

    Dec 1, 2025, 00:00

  • CO262 Utility of Minimum Dataset for Generation of Real-World Data in a Context With Evidence Gaps: The Left Ventricular Assist Devices as Destination Therapy

    Dec 1, 2025, 00:00

  • EE228 Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among At-Risk and High-Risk Adults in India

    Dec 1, 2025, 00:00

  • PCR48 Common Criticism of Patient-Reported Outcomes (PRO) in Health Technology Assessments (HTA) by the Institute for Quality and Efficiency in Healthcare (IQWiG) in Breast Cancer and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • EE473 First-Line Immunotherapies for Advanced Biliary Tract Cancer: A Systematic Review of Economic Studies

    Dec 1, 2025, 00:00

  • CO89 Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pretreated Breast Cancer: A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • MSR101 Excel Front-End, R Back-End: A Gateway to Faster Individual Patient Simulations and Probabilistic Sensitivity Analyses in Cost-Effectiveness Models for HTA

    Dec 1, 2025, 00:00

  • HTA252 NICE Decisions in the Southwest Quadrant

    Dec 1, 2025, 00:00

  • EE253 Cost-Effectiveness of High-Dose Trivalent Influenza Vaccine in the Elderly: A Cohort-Based Economic Model From the Italian NHS Perspective

    Dec 1, 2025, 00:00

  • HTA50 Automated Excel-to-R Conversion of Health Economic Models Using the REEEVR Tool: Results of Alpha Test

    Dec 1, 2025, 00:00

  • MSR62 Cost of Illness Studies Published Between 2010 and 2023 in Türkiye

    Dec 1, 2025, 00:00

  • HPR137 Mapping PBS Drug Pathways in Australia: A Framework and Interactive Tool for Category-Specific Pricing Calculations

    Dec 1, 2025, 00:00

  • EE480 Genomic Testing for Early Breast Cancer: Assessing the Value of Next-Generation Sequencing

    Dec 1, 2025, 00:00

  • CO73 DII Mentoring Project— Patient Associations as a Catalyst for Quality-Of-Life Improvement and Positive Economic Impact in Inflammatory Bowel Disease

    Dec 1, 2025, 00:00

  • SA58 Investigating Functional Status and Healthcare Resource Utilization of Patients With Cognitive Impairment Associated With Schizophrenia: Findings From a Real-World Noninterventional Study

    Dec 1, 2025, 00:00

  • MT20 Gender Inequalities in Aortic and Mitral Valve Replacement and Repair Procedures in Germany

    Dec 1, 2025, 00:00

  • MSR211 Understanding Public Values in Digital Mental Health Using the Principles, Policies, and Patients’ Framework

    Dec 1, 2025, 00:00

  • EE463 Feasibility of Building a Generic Partitioned Survival Model for Oncology: Essential Components and Technical Implementation

    Dec 1, 2025, 00:00

  • CO24 Balancing Innovation and Propriety: The Question of Copyright Holder’s Opinions on GenAI Usage While Localizing Their Intellectual Property

    Dec 1, 2025, 00:00

  • EE611 Population Reference Costs for Average Total Annual Care in the UK National Health Service for 11 Common Diseases or Conditions vs. Matched Controls

    Dec 1, 2025, 00:00

  • HPR74 European and US Drug Shortages: A Critical Analysis of Key Trends and Causes

    Dec 1, 2025, 00:00

  • CO122 Factors Associated With Response to Patient-Reported Outcome Measures: A Systematic Review of Systematic Reviews and Meta-analyses

    Dec 1, 2025, 00:00

  • MSR127 Implementing Simultaneous Maximum Acceptable Risk Thresholds (SMARTs) in Discrete Choice Experiments (DCE): A Feasible Approach to Quantify Tolerance for Multiple Risks

    Dec 1, 2025, 00:00

  • CO149 Increased Functional Impairment Associated With Generalized Anxiety Disorder (GAD): Findings From a Systematic Literature Review

    Dec 1, 2025, 00:00

  • PCR32 Bimekizumab Improves Work Productivity in Patients With Hidradenitis Suppurativa: 2-Year Results From BE HEARD EXT

    Dec 1, 2025, 00:00

  • EE432 Evaluating the Acceptability of Vignette Studies in Eliciting Utility Values for Rare Diseases: Perspectives From European HTA Agencies

    Dec 1, 2025, 00:00

  • HTA197 Importance of Decisional Context in the Health Technology Assessment (HTA) of Advanced Therapy Medicinal Products (ATMPs)

    Dec 1, 2025, 00:00

  • HPR129 Introducing an Access-Based Pricing Model to Determine Prices and Inform Price Negotiations for Newly Authorized Medicinal Products

    Dec 1, 2025, 00:00

  • HTA275 Provisional Listing of Digital Healthcare Applications Digas Improves Patients' Access to Healthcare in Germany

    Dec 1, 2025, 00:00

  • P38 "Tell Me a Story": A Randomized Study Comparing Tabulated and Narrative Presentations of a Discrete Choice Experiment

    Dec 1, 2025, 00:00

  • EE622 Proportion of the Expenses of Over-the-Counter Equivalent Drugs Among Total Healthcare an Analysis Using the Wellness-Star∗ Database

    Dec 1, 2025, 00:00

  • EE149 Comprehensive Uncertainty Assessment in Economic Evaluations of AI-Based Health Technologies: Pitfalls and Recommendations

    Dec 1, 2025, 00:00

  • RWD141 Real-World Evidence Study on the Resource Impact of Subcutaneous vs. Intravenous Atezolizumab in an NHS Cancer Center

    Dec 1, 2025, 00:00

  • PCR41 Changes in Physical Activity of Pediatric Patients Treated With Damoctocog Alfa Pegol During the Alfa-PROTECT Clinical Trial

    Dec 1, 2025, 00:00

  • EE535 Impact of Indirect Treatment Comparison (ITC) Methodology on Cost-Effectiveness of Quizartinib in Acute Myeloid Leukemia (AML) in Canada and the United Kingdom (UK)

    Dec 1, 2025, 00:00

  • HSD81 Overcoming Patient Access Barriers in Complex Conditions: Lessons From Schizophrenia for Broader Healthcare Applications

    Dec 1, 2025, 00:00

  • HPR201 The French Transitional Coverage Pathway (PECT) for Innovative Therapeutic Medical Devices: A Four-Year Retrospective Analysis

    Dec 1, 2025, 00:00

  • HPR48 Comparative Analysis of Reimbursement Decisions for Advanced Oncology Combination Therapies in England and Japan

    Dec 1, 2025, 00:00

  • HSD116 Treatment Patterns, Inadequate Disease Control, and Burden/Unmet Need Among Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program

    Dec 1, 2025, 00:00

  • SA21 Comparative Safety of B/F/TAF vs. Other Antiretroviral Therapy Regimens for Treatment-Experienced People With HIV-1: A Systematic Literature Review and Indirect Comparisons Using Multilevel Network Meta-Regression

    Dec 1, 2025, 00:00

  • HTA233 Middle East NICE Move Towards Standardized Health Technology Assessment

    Dec 1, 2025, 00:00

  • MSR223 When Excel Starts Talking Back: Unlocking the Power of Conversational AI for Health Economic Models

    Dec 1, 2025, 00:00

  • HTA55 Beyond the QALY: An Analysis of Uncaptured Benefits in NICE Oncology Technology Appraisals 2023-2025

    Dec 1, 2025, 00:00

  • HTA108 Development of a Multidimensional HTA Evaluation for the Introduction of Clesrovimab in Pediatric RSV Prevention: An Integrated Methodological Approach

    Dec 1, 2025, 00:00

  • MSR10 A Two-Stage Bayesian Approach for Real-World Cost-Effectiveness Analysis: Combining Inverse Probability Weighting With Gamma-Beta Regression Model

    Dec 1, 2025, 00:00

  • EPH196 Public Health and Economic Impact of RSVpreF Maternal Vaccination Among Infants in Five Asian Countries

    Dec 1, 2025, 00:00

  • P59 Challenges in Assessing Trade-offs Between Efficiency and Equity in the Use of Digital Health Applications for Stroke Care

    Dec 1, 2025, 00:00

  • EPH277 Validation Between Antidepressant Treatment Failure Proxy and PHQ-9 Score in Major Depressive Disorder Using a Linked Insurance Claims and Electronic Health Record Dataset

    Dec 1, 2025, 00:00

  • HPR76 Evaluating the Effectiveness of Interventions to Reduce Gender Disparities in Healthcare: An Overview of Literature Reviews

    Dec 1, 2025, 00:00

  • MSR112 From Evidence to Excel: Generative AI for Automated SLR Data Extractions

    Dec 1, 2025, 00:00

  • MSR89 Evaluating a Deep Learning Model for Classifying Pediatric Pneumonia in Israel

    Dec 1, 2025, 00:00

  • EPH135 Impact of Resmetirom on Liver Transplant Demand and Outcomes in US Patients With MASH

    Dec 1, 2025, 00:00

  • HPR107 Global Access to Innovative Medicines in 2025: Europe’s Gaps and the UK’s Continued Decline

    Dec 1, 2025, 00:00

  • EPH102 Expert Consensus on a Definition for Children With Medical Complexity in England: A Modified Delphi Panel

    Dec 1, 2025, 00:00

  • CO64 Correlation Between Extension Survival Benefits and Incremental Costs of Oncology Drugs in Portugal: A Cross-Sectional, Regression Analysis

    Dec 1, 2025, 00:00

  • MSR25 An Integrated Web-Based Approach to Survival Analysis and Extrapolation for Economic Modeling

    Dec 1, 2025, 00:00

  • EE659 Societal and Economic Impact of Long-Acting Injectable Buprenorphine (LAIB) Compared With Standard Opioid Substitution Therapy (OST) in France

    Dec 1, 2025, 00:00

  • EPH192 Prevalence of Obesity and Comorbidities Among People With Obesity in China, Japan, and EU5

    Dec 1, 2025, 00:00

  • EPH86 Estimating the Age- and Sex-Standardized Prevalence and Incidence of Depression and Anxiety in UK Adults Using the THIN Database

    Dec 1, 2025, 00:00

  • EE234 Cost-Effectiveness of an AI-Based Smartphone App for the Early Detection of Skin Cancer: A Decision Tree Analysis

    Dec 1, 2025, 00:00

  • EE339 Do The Guardrails Have Any Effect at All? An Analysis of the Impact of the 2022 FINSTG Guardrails on the German AMNOG Process

    Dec 1, 2025, 00:00

  • HPR49 Comparing the Time to Reimbursement of the Orphan Drug Evrysdi in Turkiye vs. Euro-5 Markets

    Dec 1, 2025, 00:00

  • HSD19 Can Switching From Intravenous (IV) to Subcutaneous (SC) Formulations Save Time and Resources? A Service Impact Model (SIM)

    Dec 1, 2025, 00:00

  • HTA224 Limited Duration vs. Treat-to-Progression Approaches for New Therapies in Hemato-oncology: Impact at HTA

    Dec 1, 2025, 00:00

  • EE289 Costs Associated With the Administration, Postinfusion Monitoring, and Management of Adverse Events (AEs) Related to Novel Drugs for Second-Line (2L+) Treatment of Small-Cell Lung Cancer (SCLC)

    Dec 1, 2025, 00:00

  • PCR52 Content Validation of a Modified PozQoL for Assessing HIV Therapies

    Dec 1, 2025, 00:00

  • EE111 Budget Impact of Nivolumab Plus Ipilimumab Plus Chemotherapy as First-Line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer in Switzerland

    Dec 1, 2025, 00:00

  • HSD8 Assessing the Environmental Value of Semaglutide: Reduction in GHG Emissions Resulting From the Treatment of Obese Individuals With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • EE664 Societal Value of Intravitreal Injections for Retinal Vascular Diseases in the National Reimbursement Drug List in China

    Dec 1, 2025, 00:00

  • EE44 All-Cause Healthcare Resource Use in Recurrent Respiratory Papillomatosis: A Claims-Based Comparison With Matched Controls

    Dec 1, 2025, 00:00

  • HTA91 Correlation of Intermediate Clinical Endpoints (ICES) For Overall Survival (OS) In Localized or Locally Advanced Prostate Cancer (LPC/LAPC): Analysis of Individual Real-World Data (RWD)

    Dec 1, 2025, 00:00

  • PCR109 Health Utility and Indirect Costs of Neuromuscular Disease Through a Patient-Centered Lens: A National Patient and Caregiver Survey

    Dec 1, 2025, 00:00

  • CO132 Herpes Zoster Hospitalization Rates in Germany: A Retrospective Database Analysis

    Dec 1, 2025, 00:00

  • MSR185 ShinyMMD: An Open-Source Shiny Web Application for a Computer Simulation Model for Type 2 Diabetes and Its Complications

    Dec 1, 2025, 00:00

  • APPRAISE: A Tool for Appraising Potential for Bias in Real-World Evidence Studies on Medication Effectiveness or Safety

    Dec 1, 2025, 00:00

  • SA99 Understanding Heterogeneity in the Classification of Locally Advanced Cancer: Analysis of Clinical Trial Records From the Past 2 Years (2023-2025)

    Dec 1, 2025, 00:00

  • EE504 Healthcare Resource Use and Costs Associated With Herpes Zoster Among Adults Aged 18 Years or Older in England: A Large Retrospective Cohort Study Clinical Practice Research Datalink 2012-2019

    Dec 1, 2025, 00:00

  • EE275 Cost-Effectiveness of Smartphone-Based Screening for Obstructive Sleep Apnea: A Markov Model Analysis From the German Statutory Health Insurance Perspective

    Dec 1, 2025, 00:00

  • EE657 Societal and Economic Burden of Obesity in Bulgaria

    Dec 1, 2025, 00:00

  • RWD177 Switching Within vs. Outside the TNFi Class Following TNFi Failure in Patients With Crohn’s Disease (CD) in Europe: A Meta-Analysis of Real-World Outcomes

    Dec 1, 2025, 00:00

  • SA97 Therapeutic Potential of Bispecific Antibodies in Adenocarcinoma: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA176 Health Technology Assessments of Oncology Orphan and Advanced Therapies: The Case for Incorporating Real-World Evidence Patient-Reported Outcomes and Indirect Treatment Comparisons Into Joint Clinical Assessment Submissions

    Dec 1, 2025, 00:00

  • HSD105 Subcutaneous vs. Intravenous Administration in Oncology: A Literature Review of Impacts on Patients, Providers, and Hospitals

    Dec 1, 2025, 00:00

  • HTA56 Beyond the Surfa Health Technology Assessment and Reimbursement for Inflammatory or Autoimmune Disorders With Cosmetic and Dermatological Manifestations

    Dec 1, 2025, 00:00

  • HTA123 Efficient and High-Quality Decision Making: An Exploration of Disease-Specific Reference Models at NICE

    Dec 1, 2025, 00:00

  • HPR157 Paying for Advanced Therapy Medicinal Products: Are Spreading Payments Over Time the Solution?

    Dec 1, 2025, 00:00

  • MSR98 Evaluating Treatment Benefit and Tolerability Based on Responder and Time-to-Event Analysis of Patient-Reported Outcomes in Cancer Clinical Trials: A Scoping Review

    Dec 1, 2025, 00:00

  • HTA18 Acceptance of Artificial Intelligence in Evidence and Dossier Development by Global HTA Agencies

    Dec 1, 2025, 00:00

  • MSR104 Exploring Nonproportional Hazards Multi-Level Network Meta-Regression (ML-NMR) for Survival Extrapolations in Oncology

    Dec 1, 2025, 00:00

  • EE108 Budget Impact of Introducing Accuchek® Smartguide Real-Time Continuous Glucose Monitoring (RtCGM) Solution for Diabetes Management in Portugal

    Dec 1, 2025, 00:00

  • HTA21 Adapting HTA Frameworks for Precision Medicine: Methodological Advances in the UK and EU4

    Dec 1, 2025, 00:00

  • HTA320 The Impact of Using England Real-World Evidence to Establish the NICE Severity Modifier in Metastatic Urothelial Carcinoma (MUC)

    Dec 1, 2025, 00:00

  • EE549 Incorporating Equity-of-Access Into Health Economic Evaluations: Surgical Task-Shifting for C-Sections in Sierra Leone

    Dec 1, 2025, 00:00

  • EPH44 Chronic Kidney Disease in Type-2 Diabetes Patients: A Population-Based Descriptive Study

    Dec 1, 2025, 00:00

  • HTA128 EU HTA JCA PICO Consolidation Process Examples: Key Trends and Remaining Uncertainties

    Dec 1, 2025, 00:00

  • MT48 What Is the HTA Process for Medical Technologies in Scotland?

    Dec 1, 2025, 00:00

  • HTA353 Utilization of Real-World Evidence (RWE) in AMNOG Dossiers Following the 2024 GBA Revision of Module 3 Requirements

    Dec 1, 2025, 00:00

  • CO154 Infective Endocarditis Following FRANCE-TAVI Insights

    Dec 1, 2025, 00:00

  • HPR11 Accelerating RTOR in Oncology: The AIM Model for Agile Trial Operations

    Dec 1, 2025, 00:00

  • CO125 Garbage In, Garbage Out: Can AI Reduce the Impact of Human Error in eCOA Localized Text Migration?

    Dec 1, 2025, 00:00

  • RWD44 COPD-Asthma Overlap in Brazilian Private Healthcare: Clinical Profiles and Outcomes from a Real-World Analysis

    Dec 1, 2025, 00:00

  • PCR84 Evaluating the Role of Patient-Reported Outcomes in Phase 4 Clinical Trials: Trends, Applications, and Implications for Postmarketing Surveillance

    Dec 1, 2025, 00:00

  • EE280 Cost-Effectiveness of TEVAR With Active Control in Patients With TAA and TBAD: A Japanese Public Healthcare Payer Perspective

    Dec 1, 2025, 00:00

  • EE691 The Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients With Early Breast Cancer

    Dec 1, 2025, 00:00

  • CO31 Breast Cancer Overall Survival in France

    Dec 1, 2025, 00:00

  • EE737 Treatment Patterns of Rare Immunodeficiencies With Special Regard to Antibiotics: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • HTA230 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2024

    Dec 1, 2025, 00:00

  • CO204 Real-World Efficacy Outcomes for Patients With Relapsed/Refractory Multiple Myeloma (RRMM) From the Flatiron Health Database

    Dec 1, 2025, 00:00

  • EE735 Treatment Patterns and Economic Outcomes in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US: A Real-World Claims Database Analysis

    Dec 1, 2025, 00:00

  • HTA165 Global Adoption of Dynamic Transmission Models in Infectious Disease Vaccine Submissions: A Comparative Analysis Across the EU5 North America and Scandinavia

    Dec 1, 2025, 00:00

  • HSD74 Missed Opportunities in the Diagnosis and Management of Stage 3 Chronic Kidney Disease in General Practi Insights From the Italian THIN Database

    Dec 1, 2025, 00:00

  • EE603 Organizational and Environmental Impact of Switching From Intravenous to Subcutaneous Immune Checkpoint Inhibitors (ICIs) in Fran A Real-World Analysis Using PMSI Data

    Dec 1, 2025, 00:00

  • P25 Optimizing the Use of Excess Hazard Models in Survival Analysis: Considering Disease Severity and Follow-up Maturity

    Dec 1, 2025, 00:00

  • EE133 Clinical Management and Outcomes of Patients in England With eGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Observational Study and Its Impact on UK Health Technology Assessments

    Dec 1, 2025, 00:00

  • PCR247 Treatment Discontinuation in Idiopathic Pulmonary Fibrosis: A Systematic Review of Antifibrotic Drug Use and Tolerability

    Dec 1, 2025, 00:00

  • CO65 Costs and Consequences of Cardiovascular Toxicity Due to Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • PT30 An Exploration of Implementing Herd Immunity Into Static Models for Economic Evaluation of Vaccines

    Dec 1, 2025, 00:00

  • RWD6 A Record-Level Risk Metric for Partially Synthetic Clinical Data Using Inverse-Square Similarity Decay

    Dec 1, 2025, 00:00

  • MT42 The Unique Value of Detecting Preeclampsia: Comparing Health Economic Analyses of Novel Diagnostics With the ISPOR Value Flower

    Dec 1, 2025, 00:00

  • PCR40 Caregiver QALYs Deserve Better: Why It's Time for a Methodological Rethink

    Dec 1, 2025, 00:00

  • RWD136 Potential Nephrocalcinosis Risk Linked to Nusinersin: Insights from FAERS-Based Signal Detection and Molecular Docking

    Dec 1, 2025, 00:00

  • HTA339 Transparency Tested: Conflict of Interest in EU HTA

    Dec 1, 2025, 00:00

  • HTA247 Navigating Parallel Joint Scientific Consultations Under EU HTA Regulation: Key Internal Considerations for Health Technology Developers

    Dec 1, 2025, 00:00

  • EE136 Comparative Assessment of Health-Related Quality of Life Among the Lebanese Population Pre- and Post-COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • Health-Economic Evaluation of COVID-19 Updated Booster Vaccination and Age-Related Cost Outcomes

    Dec 1, 2025, 00:00

  • EE66 Assessing Treatment Efficiency Indicated in Rare Diseases: Learning From the CEESP Has Economic Opinions

    Dec 1, 2025, 00:00

  • EE306 Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria

    Dec 1, 2025, 00:00

  • CO113 Evolution of MRD in Hemato-Oncology Clinical Development

    Dec 1, 2025, 00:00

  • EE357 Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) in India: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • RWD133 Parental Vaccine Hesitancy in Children With Comorbidities: A Comparative Analysis

    Dec 1, 2025, 00:00

  • MSR131 Improving Kidney Exchange Program Effectiveness and Equity by Using Allele and Eplet HLA Compatibility Technologies

    Dec 1, 2025, 00:00

  • EE223 Cost-Effectiveness and Budget Impact of High-Dose Trivalent Influenza Vaccine Efluelda® in Older Adults: A Greek Healthcare System Perspective

    Dec 1, 2025, 00:00

  • RWD191 Validating a Medication Adherence Index in Large Urban Population

    Dec 1, 2025, 00:00

  • HPR44 Citizens’ Send Messages to Policy Makers Related to Primary Healthcare Practices: First Results From the Implementation of the Patient-Reported Indicator Surveys PaRIS in Greece

    Dec 1, 2025, 00:00

  • EE262 Cost-Effectiveness of Modifying Cardiovascular Disease Risk Factors in Qatar Using the Productivity-Adjusted Life Years (PALY) Metric

    Dec 1, 2025, 00:00

  • EE529 Impact of Dupilumab on Mental Health Service Utilization in Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study

    Dec 1, 2025, 00:00

  • EE245 Cost-Effectiveness of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective

    Dec 1, 2025, 00:00

  • HTA10 A New Approach for Modeling the Complexity of the Impact of Caring Using the Family and Caregiving Effects

    Dec 1, 2025, 00:00

  • CO23 Association Between Objective Response and Overall Survival in BRAF V600e-Mutant Metastatic Colorectal Cancer: An Analysis of the BEACON CRC Trial

    Dec 1, 2025, 00:00

  • EE703 The Economic Burden of Parkinson's Disease in the Netherlands: From Societal Impact to Investments in Health Solutions

    Dec 1, 2025, 00:00

  • HTA268 Patient-Centered PICO Scoping in EU HTA: A Pilot Study for Structured Consensus Building Using a Delphi Panel

    Dec 1, 2025, 00:00

  • EE644 Reducing the Transmission and Annual Burden of Influenza in the UK With Baloxavir Marboxil: A Cost-Effectiveness Analysis Using Evidence From the CENTERSTONE Trial

    Dec 1, 2025, 00:00

  • HSD49 Evaluation of the Effectiveness of Targeted Radiofrequency Therapy in Impingement Syndrome

    Dec 1, 2025, 00:00

  • MSR22 AI-Assisted Time-to-Event Projection: A Case Study and Broader Potential

    Dec 1, 2025, 00:00

  • P62 EQ-5D Analysis in a Rare Disease: Utilities Across Disease Stages in Multiple-System Atrophy

    Dec 1, 2025, 00:00

  • PCR136 Improving the Conceptual Coverage of the 15-item Penn Parkinson’s Daily Activity Questionnaire (PDAQ-15) for Use in the Mild-to-Moderate Lewy Body Dementia Population

    Dec 1, 2025, 00:00

  • EE227 Cost-Effectiveness as Part of the German AMNOG Process Analyzing the 2025 SVR Proposal and Its Implementation Challenges

    Dec 1, 2025, 00:00

  • EE521 How Cost-Effectiveness and Budget Impact Drive Pricing and Reimbursement: Insights From an International Comparative Study

    Dec 1, 2025, 00:00

  • SA93 The Health Economic Case for AI in Radiology: A Systematic Review and Appraisal of Evaluation Quality and Methods

    Dec 1, 2025, 00:00

  • PCR140 Integrating Patient-Reported Outcome Measures and Patient Experience Into Health Technology Assessment: A Path Towards Patient-Centered Decision Making

    Dec 1, 2025, 00:00

  • PCR166 Optimizing a New Patient-Reported Outcome Instrument for Proliferative Diabetic Retinopathy: A Psychometric Study

    Dec 1, 2025, 00:00

  • HPR36 Bridging the Access Gap: The Role of Non-Public Access Partnerships for Oncology Treatments in China

    Dec 1, 2025, 00:00

  • EPH20 Assessing Pharmaceutical Innovation in Europe: Therapeutic Advances vs. Unmet Public Health Need

    Dec 1, 2025, 00:00

  • HTA47 Assessment of Severity Modifiers vs. End-of-Life Criteria in Oncology

    Dec 1, 2025, 00:00

  • HSD15 Bridging Systemic Access Gaps for Cancer Medicines: A Policy Perspective From the Republic of Moldova

    Dec 1, 2025, 00:00

  • EE26 A Nutrient-Dense Formula in Undernourished Children in Indonesia: An Effective Cost-Saving Strategy

    Dec 1, 2025, 00:00

  • MT29 Mortality and Economic Burden of Revisions After Proximal Femoral Fracture Fixation

    Dec 1, 2025, 00:00

  • HTA100 Cost-Utility Analysis of Including X-linked Adrenoleukodystrophy in the Spanish Newborn Screening Program

    Dec 1, 2025, 00:00

  • HTA297 Shifts in the French HTA Transparency Committee’s Use of Indirect Comparisons: Insights From a Systematic Review of the French Transparency Committee (TC) Opinions

    Dec 1, 2025, 00:00

  • MT4 AI-Enabled Wearables for Fitness and Preventive Health

    Dec 1, 2025, 00:00

  • PCR9 A Review of Approaches to Select Instruments and Items to Measure Patient Reported Tolerability in Clinical Trials in Oncology

    Dec 1, 2025, 00:00

  • HTA313 The Acceptability of Wearables in Remote Monitoring According to Health Technology Assessment HTA Bodies

    Dec 1, 2025, 00:00

  • CO168 Nephrotoxicity of Antisense Oligonucleotide Therapies in Duchenne Muscular Dystrophy: A Warning or a Challenge?

    Dec 1, 2025, 00:00

  • OP10 Global Access Licensing: An Expert Interview Study with Scientists-Inventors and Directors of Technology Transfer Offices Involved in the Development and Commercialization of COVID-19 Vaccines

    Dec 1, 2025, 00:00

  • EE240 Cost-Effectiveness of Coblation Intracapsular Tonsillectomy in the Management of Sleep-Disordered Breathing and Recurrent Tonsillitis: A Brazilian Perspective

    Dec 1, 2025, 00:00

  • PCR176 Patient Perspectives on Unmet Needs in mCRPC: Emphasizing Improved Quality of Life and Delay in Chemotherapy

    Dec 1, 2025, 00:00

  • PCR132 Impact of Shared Treatment Decision Making Between Physicians and Patients on Treatment Satisfaction in Hypertension

    Dec 1, 2025, 00:00

  • EPH247 The Incidence, Mortality, and Survival of Malignant Non-Small Cell Lung Cancer (NSCLC) in the United States: A Surveillance Epidemiology and End Results (SEER) 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • EPH35 Cardiovascular Event Rate and Mortality Among Primary-Prevention Hypercholesterolemia Patients in Japan

    Dec 1, 2025, 00:00

  • RWD37 Comorbidities As a Risk Predictor of Kidney Disease Progression Among Patients Diagnosed With Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • MSR117 High-Fidelity Synthetic Patient Pathway Generation and Validation for NSCLC Using A Tabular Variational Autoencoder (TVAE)

    Dec 1, 2025, 00:00

  • EE650 Resource Utilization Among Patients With Epidermolysis Bullo Preliminary Findings From Seven European Countries

    Dec 1, 2025, 00:00

  • HPR163 Price Implications of the Most-Favored Nation Policy on US Oncology Drug Prices

    Dec 1, 2025, 00:00

  • RWD72 Economic Burden of Prostate Cancer Overall and by Stages Based on the French Real-World Nationwide Medico-Administrative Database (SNDS)

    Dec 1, 2025, 00:00

  • PCR68 Elevating the Patient Perspective: Quantifying First-Line Preferences in Locally Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Using the Threshold Technique

    Dec 1, 2025, 00:00

  • HPR96 Fit-for-Purpose Real-World Data: Lessons From FDA QCARD and EMA Data Quality Framework

    Dec 1, 2025, 00:00

  • HTA22 Adapting to Change: Analysis of Trend Estimation in AMNOG Dossiers Under Revised GBA Guidelines

    Dec 1, 2025, 00:00

  • HTA323 The Landscape of the Use of Artificial Intelligence and Machine Learning (AIMI) Methods in Health Technology Assessment (HTA) Submissions

    Dec 1, 2025, 00:00

  • HTA371 Why TSD26 Matters: How Accurate Was Clinical Expert Opinion in Estimating Long-Term Outcomes?

    Dec 1, 2025, 00:00

  • HTA294 Role of Technical Engagement in NICE Process Under Proportionate Approach to Technology Appraisals

    Dec 1, 2025, 00:00

  • HTA51 Balancing Fit and Accuracy: Evaluating Survival Model Projections With Immature Data in Health Technology Assessments

    Dec 1, 2025, 00:00

  • HTA186 HTA League of Nations: Which Bodies Were Most Likely to Approve Submissions and for What Disease Areas?

    Dec 1, 2025, 00:00

  • PCR59 Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • PCR115 Health-Related Quality of Life for Patients With Transthyretin Amyloid Cardiomyopathy: A Real-World Study in Europe, Canada, and Japan

    Dec 1, 2025, 00:00

  • HTA189 HTA Readiness for Tumor-Agnostic Therapies: Lessons From Analogues Across Major Markets

    Dec 1, 2025, 00:00

  • CO224 Systematic Literature Review (SLR) of Efficacy, Health-Related Quality of Life (HRQoL), and Safety of Immunotherapies for Perioperative Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • CO150 Indirect Treatment Comparison of Biochemical Control Between Pasireotide Long-Acting Release and Pegvisomant as Second-Line Therapies for Acromegaly, Based on Real-World Evidence

    Dec 1, 2025, 00:00

  • EE667 Socioeconomic Burden Among Children and Adults With Achondroplasia in Europe and Latin America

    Dec 1, 2025, 00:00

  • MSR149 Modeling Price Premiums of Oncology Drugs in Germany: A Cross-Validated Analysis Using XGBoost

    Dec 1, 2025, 00:00

  • HPR177 Review of Rare Disease Policy Developments in Europe and Türkiye 2020-2025 in the Context of Innovative Orphan Drugs

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7 (current)
  • 8
  • 9
  • 10
  • »